Research ArticleMultiple Sclerosis

BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions

See allHide authors and affiliations

Science Translational Medicine  06 Dec 2017:
Vol. 9, Issue 419, eaam7816
DOI: 10.1126/scitranslmed.aam7816

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Mapping active myelination with BCAS1

Neuronal axon demyelination causes motor and cognitive impairments in multiple sclerosis (MS) and other demyelinating disorders. Although remyelinating strategies have been proposed, the lack of markers to detect areas of active myelination hampers the development of effective therapies. Fard et al. show that myelinating oligodendrocytes constitute a unique population expressing breast carcinoma amplified sequence 1 (BCAS1) in rodent and human brain tissue. In brain samples from deceased MS patients, BCAS1+ cells are present around lesions, suggesting that remyelination might occur during MS and that BCAS1 expression could be used to track responses to remyelinating compounds for treating demyelinating disorders.